Hologic, Inc. (NASDAQ:HOLX) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Hologic, Inc. (NASDAQ:HOLX) have earned a consensus rating of “Moderate Buy” from the sixteen brokerages that are covering the firm, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a hold recommendation, eight have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $88.92.

A number of research analysts recently issued reports on HOLX shares. William Blair reiterated an “outperform” rating on shares of Hologic in a research note on Monday, January 13th. JPMorgan Chase & Co. raised their price target on Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. Mizuho dropped their price objective on Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 5th. Evercore ISI increased their target price on Hologic from $78.00 to $82.00 and gave the company an “in-line” rating in a research note on Tuesday, October 1st. Finally, Leerink Partners dropped their price target on Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th.

Insider Buying and Selling at Hologic

In other news, COO Essex D. Mitchell sold 24,856 shares of the stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the transaction, the chief operating officer now directly owns 27,957 shares of the company’s stock, valued at approximately $2,134,237.38. This represents a 47.06 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 1.75% of the company’s stock.

Institutional Trading of Hologic

A number of large investors have recently bought and sold shares of HOLX. Wolff Wiese Magana LLC bought a new stake in Hologic during the third quarter worth about $25,000. General Partner Inc. acquired a new position in shares of Hologic in the 4th quarter worth approximately $26,000. Groupama Asset Managment grew its position in Hologic by 9.9% during the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 2,999 shares during the last quarter. Sunbelt Securities Inc. bought a new stake in Hologic during the 2nd quarter worth approximately $37,000. Finally, First Horizon Advisors Inc. increased its holdings in Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after purchasing an additional 134 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors.

Hologic Stock Performance

HOLX opened at $69.73 on Thursday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69. The company has a market cap of $15.82 billion, a PE ratio of 20.94, a price-to-earnings-growth ratio of 2.44 and a beta of 0.97. The stock has a 50-day moving average of $74.65 and a 200-day moving average of $78.38. Hologic has a 52-week low of $68.61 and a 52-week high of $84.67.

Hologic (NASDAQ:HOLX) last announced its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The firm had revenue of $987.90 million during the quarter, compared to analysts’ expectations of $978.25 million. During the same quarter in the prior year, the business earned $0.89 earnings per share. The company’s revenue was up 4.5% on a year-over-year basis. As a group, equities research analysts forecast that Hologic will post 4.28 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.